Blood pressure, arterial stiffness and endogenous lithium clearance in relation to AGTR1 A1166C and AGTR2 G1675A gene polymorphisms by Cwynar, Marcin et al.
Journal of the Renin-Angiotensin-
Aldosterone System
 April-June 2016: 1 –12
© The Author(s) 2016
Reprints and permissions: 
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/1470320316655669
jra.sagepub.com
Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons 
Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, 
reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and  
Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction
Results from several recent post-hoc analyses of prospec-
tive data showed the apparently divergent results concern-
ing the relation between the level of sodium consumption 
and cardiovascular outcome. First, based on a large cross-
European cohort of nuclear families, higher consumption 
of sodium in healthy subjects did not translate into a greater 
risk of cardiovascular events.1 Another analysis of data 
revealed a J-shaped relationship between sodium intake 
and cardiovascular complications.2 Thus far, neither the 
concordant nor the discrepant aspects of these analyses 
have found a possible unifying mechanistic explanation. 
Sodium load influences blood pressure values and facili-
tates damage to target organs.3,4 The mechanisms involved 
include an interaction between environmental factors such 
as sodium intake, and changes in renal sodium handling 
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caused, apart from kidney injuries, by mutations of a num-
ber of genes encoding cytoskeleton proteins, ion channels 
or hormones taking part in sodium metabolism.5,6
Angiotensin II (AT II), the effector hormone of the 
renin-angiotensin-aldosterone axis (RAA) axis, which is 
the main hormonal regulatory system in sodium-water 
homeostasis, exerts its biological effect via specific AT1 
and AT2 receptors. Accumulating data established the role 
of the AT1 receptor in the classic actions of AT II including 
vasoconstriction and cardiovascular hypertrophy, whereas 
the AT2 receptor is suggested to exert direct functions in 
vasodilation and antigrowth effects.7 The above observa-
tion raises the possibility that genetic variability in the AT1 
and AT2 receptor genes (AGTR1 and AGTR2) has an 
impact on blood pressure, arterial stiffness and left ven-
tricular hypertrophy. Such impact may indeed be mediated 
by sodium-dependent mechanisms and involve influence 
on renal sodium handling.
In the past all studies which investigated the relation-
ship between target organ damage and sodium renal han-
dling, and which involved endogenous lithium clearance 
methodology, were performed either in the general popu-
lation of healthy adults8 or untreated hypertensives,9 and 
many experts advised against application of this method-
ology, or all similar studies in treated hypertensive 
patients, altogether.10,11 On the other hand, as demon-
strated by Hollenberg et al.12 and Burnier et al.,13 many 
of the pivotal antihypertensive medications such as 
Angiotensin converting enzyme (ACE)-inhibitors and 
angiotensin receptor blockers, do not materially change 
the inferences from the assessment of renal sodium han-
dling in patients with high sodium intake as compared to 
results from medication-naive individuals, leaving diuret-
ics as the only classes of medications which are deemed 
to distort the results based on endothelium lithium clear-
ance methodology. In daily practice we usually deal with 
treated hypertensive, rather than treatment-naive, patients, 
and still less with the untreated healthy adults. And it is 
the treated patients who carry the bulk of the burden of 
cardiovascular risk. Thus, prepared to face criticism, we 
decided to study the relationship between renal sodium 
handling, angiotensin receptor gene polymorphisms and 
arterial stiffening in a group of treated hypertensive 
patients with high sodium intake, free from diuretics.
Methods
Study population
The study was approved by the Bioethical Committee of 
Jagiellonian University (KBET/141/B/2009). From April 
2010–May 2013 in the framework of the National Research 
Centre grant (Nr. N N402 533239), we enrolled 140 hyper-
tensive patients followed up at the reference hypertension 
clinic of the University Hospital in Krakow. The study 
design has been described in detail elsewhere.14 Briefly, all 
patients were requested to complete a standard epidemio-
logic questionnaire including detailed medical history, 
antihypertensive medications, and socioeconomic and 
demographic characteristics. The patients provided written 
informed consent to participate in the study. The patients 
with a history of malignancy, decompensated chronic dis-
eases, cardiomyopathy of unknown aetiology, haemody-
namically significant valvular heart disease or secondary 
hypertension were excluded from the study. To avoid inter-
ference between sodium excretion/reabsorption and the 
use of diuretic agents, only the patients not receiving long-
term diuretic treatment or patients in whom hypertension 
was sufficiently well-controlled to allow discontinuation 
of diuretic treatment at least five days before enrolment 
were included in the study. The five-day washout period 
was deemed sufficient to eliminate an influence of diuret-
ics on the analysed parameters.15
Nine patients were excluded from the statistical analy-
sis: four because of diuretic treatment within five days 
before the 24-hour urine collection, three because of fail-
ure to complete the urine collection and two because of 
high serum lithium levels (>2.0 µmol/l) and urinary lith-
ium levels (>25.0 µmol/l) that may have indicated external 
contamination or high dietary lithium intake. Thus, 131 
subjects were included in the statistical analysis.
Blood pressure and vascular stiffness 
measurements
Blood pressures were measured using the Omron HEM-
705 device (Omron Healthcare, Kyoto, Japan). In every 
patient the measurements were performed on a non-domi-
nant arm in a sitting position, after a minimum of 10-min-
ute rest; blood pressure values were calculated as a mean 
of three measurements. Pulse pressure (PP) was calculated 
as a difference of the mean systolic blood pressure (SBP) 
and the mean diastolic blood pressure (DBP), and the 
mean blood pressure (MBP) was calculated as a sum of 
DBP and one-third of PP.
The measurements of arterial properties were performed 
by a one observer with the patient after a 15-minute rest and 
included central pulse wave analysis (PWA) (PWA module 
of the SphygmoCor 6.31 device; AtCor Medical Pty Ltd, 
West Ryde, New South Wales, Australia) and pulse wave 
velocity (PWV) (PWV module of the Complior device; 
Colson, France). PWA recordings were performed in eight-
second periods using peripheral arterial tonometry. The 
measurements were performed on the radial artery of the 
non-dominant upper extremity using a SPC-301 microma-
nometer (Millar Instruments, Inc., Houston, Texas, USA). 
The following of the obtained parameters were considered 
in the statistical analyses: blood pressure parameters, 
including: central systolic blood pressure (SBPC), central 
diastolic blood pressure (DBPC), central mean blood pres-
sure (MBPC) and central pulse pressure (PPC), and arterial 
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stiffness parameters, including: aortic pulse wave augmen-
tation (AG) and peripheral (AIxP) and central (AIxC) aortic 
pulse wave augmentation indexes. AG (mm Hg) was calcu-
lated as a difference of the first and second systolic peak on 
the ascending arm of the aortic pulse wave. AIxP (%) and 
AIxC1 (%) were calculated as a quotient of the first and sec-
ond systolic peak on the ascending arm of the radial and 
aortic pulse wave, and AIxC2 (%) was calculated as a prod-
uct of AG and PPC. The averaged pulse waves showing 
<5% difference of the height and width of systolic and dias-
tolic portions or >80 mV amplitude of the wave signal, 
were classified as normal. PWV (m/s) was measured 
between carotid and femoral arteries. Mean values of 10 
consecutive measurements were included in the statistical 
analysis.
Echocardiography
Structural and functional measurements of left ventricular 
(LV) myocardium were performed using transthoracic, 2D 
echocardiography with Doppler measurements (Vivid 4, 
General Electric, Wauwatosa, Wisconsin, USA), with a 
2.5–3.5 MHz transducer. Pulsed-wave Doppler with a gate 
positioned on the mitral valve was used to assess the early 
(E) and late (A) mitral inflow, their proportion (E/A) and 
the E wave deceleration time (DT). The isovolumetric 
relaxation time (IVRT) was measured as the time from the 
end of aortic inflow to the beginning of the mitral inflow. 
Tissue Doppler imaging was used for the measurements of 
the movements of the mitral annulus with a gate positioned 
on the basal segment of the ventricular septum. These 
measurements included early diastolic velocity (e’), maxi-
mum velocity after atrial contraction (a’) and their propor-
tion (e’/a’); the E/e’ index was also calculated. LV ejection 
fraction was assessed using the Simpson method. Stroke 
volume (SV) was calculated using planimetry in the four 
chamber apical view. Diastolic LV dysfunction was diag-
nosed on the basis of echocardiographic parameters for 
persons >50 years according to the European Society of 
Cardiology (ESC) guidelines.16
Clinical measurements
Anthropometric measurements, including: height, body 
weight, waist circumference and hip circumference were 
obtained in every patient. Body mass index (BMI) was cal-
culated as a ratio of the body weight (kg) and a square of 
the height (cm). Waist-to-hip ratio (WHR) was calculated 
as the ratio of the waist and hip circumferences. In the 
morning of cardiovascular measurements, a fasting blood 
sample was obtained from each patient for serum measure-
ments of glucose, glycosylated haemoglobin A1c (HbA1C), 
serum lipid levels, N-terminal natriuretic propeptide B 
(NT-proBNP), sodium, potassium, creatinine and lithium. 
One day before, the patients recruited to the study 
completed a 24-hour urine collection to measure 24-hour 
excretion of sodium (Na24), potassium, creatinine, lithium, 
and albumin.
Renal sodium handling and genetic studies
We measured serum and urinary lithium concentrations 
necessary for the calculations of lithium clearance with 
atomic absorption spectrometry (AAS) using the 5100ZL 
AAS equipment (Perkin-Elmer Inc., Waltham, 
Massachusetts, USA). Urinary lithium levels were detected 
using flame injection AAS (FI-AAS) and graphite furnace 
AAS (GF-AAS) for urine measurements in the case of 
lithium concentrations below the level of 10 µg/l. Serum 
lithium concentrations were detected with GF-AAS. The 
analytic parameters of FI-AAS in urine were: limit of 
detection (LOD) at 1.4 µg/l, precision at Li concentration 
of 25.0 µg/l at 5%, recovery at 95–100%. The analytic 
parameters of GF-AAS for urine samples were as follows: 
LOD at 0.9 µg/l, precision at Li concentration of 10.0 g/l at 
5%, recovery at 94%, and for serum, LOD 0.4–0.8 µg/l, 
precision at Li concentration of 5.0 g/l at 9%, recovery at 
96%. Creatinine, sodium and lithium clearance (C) values 
were calculated using the formula:
C V U Px x x= × /
where V (m/min) was a 24-hour urine volume calculated 
per minute and Ux and Px were molar creatinine, sodium 
or lithium concentrations in urine and serum, respec-
tively. High lithium clearance or a small difference 
between the lithium and sodium clearances indicates 
increased capacity for renal excretion of excessive 
sodium loads. Fractional sodium excretion (FENa) and 
fractional lithium excretion (FELi) were expressed as per-
centages derived from the product of sodium or lithium 
clearance, respectively, and creatinine clearance:
FE 1 C Cx x CR% //( )= ×00
where x represents lithium or sodium. Since lithium is 
transported across the membranes of proximal renal 
tubular cells using the same pathways as sodium ions, 
FELi is a very accurate marker of glomerular filtration 
rate (GFR)-dependent sodium reabsorption in the proxi-
mal tubules. Low FELi indicates higher sodium and water 
load reabsorbed in the proximal tubule, which results in a 
lower sodium and water load filtered to the distal tubule. 
Measurements of both FELi and FENa allow for estimating 
the fractional distal sodium reabsorption (FDRNa) using 
the formula:
FDR FE  FE FE 1Na Li Na Li= ( )( )×− / 00
FDRNa is an estimate of sodium that is not reabsorbed in 
the proximal tubule, but undergoes reabsorption in the 
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post-proximal segments of the renal tubules. High FDRNa 
indicates higher sodium and water load reabsorbed in the 
distal tubule, which results in a lower sodium and water 
load that is filtered and subsequently excreted with urine.17
Genetic studies were performed at the Department of 
Neurogenetics, the Chair of Neurology of the Jagiellonian 
University using peripheral blood collected on ethylenedi-
aminetetraacetic acid (EDTA). Genomic DNA was iso-
lated using the QIAamp DNA Blood Mini Kit (QIAGEN, 
Germantown, Maryland, USA). We assayed the A1166C 
polymorphism of the AGTR1 gene and G1675A of the 
AGTR2 gene with the real-time polymerase chain reaction 
(RT PCR) performed with ViiA 7 Real Time PCR System 
(Life Technologies, Carlsbad, California, USA). We used 
the TaqMan Pre-Designed SNP Genotyping Assay. The 
methodology has been described in detail elsewhere.18
Statistical analysis
Database management and statistical analyses were per-
formed using the SAS System 9.3 software (SAS Institute 
Inc., Cary, North Carolina, USA). The distributions of 
the analysed quantitative variables were compared with 
the normal distribution using the Shapiro-Wilk and 
Kolmogorov-Smirnov tests. In the descriptive statistics the 
quantitative data were expressed as mean values and 
standard deviations (for the data with normal distribution) 
or as median values and interquartile ranges (for the data 
that did not fulfil the criteria of normal distribution). The 
qualitative data were expressed as proportions. For the 
comparisons of the mean values in the groups of patients 
the Student’s t-test was used. Alternatively, Wilcoxon and 
median tests were used in case of the skewed distribution 
of quantitative variables in the subgroups. The χ2 Pearson’s 
test or Fisher’s test was used for qualitative variables. The 
correlations of quantitative sodium parameters were ana-
lysed using the standardised Spearman’s correlation analy-
sis. Simple linear regression analysis was performed to 
identify the factors associated with the analysed sodium 
parameters (FELi, FDRNa, Na24).
The conformance of the distributions of the analysed 
genotypes with the distributions estimated using the 
Hardy-Weinberg principle was confirmed using χ2 
Pearson’s test. Selected parameters of blood pressure and 
arterial stiffness were compared for the AGTR1 A1166C 
and AGTR2 G1675A gene polymorphisms using vari-
ance analysis in the whole study group and separately for 
male and female patients. The G1675A alleles are located 
on chromosome X, thus, to achieve a homogenous genetic 
background across genders the homozygotic women 
were analysed together with respective male groups. 
Then a multifactorial regression model (PROC GENMOD 
module of the SAS 9.2 software)19 was applied to include 
the dependent variables and to calculate the standardised 
mean values and standard measurement error for the 
respective genotypes and allele carriers. In the subse-
quent analyses a multifactorial regression model was 
applied to analyse the interactions between genetic and 
environmental factors with respect to blood pressure and 
parameters of arterial stiffness.
Our study was an association study with allelic vari-
ants treated as classification variables. The primary out-
come measure was e.g. central augmentation index 
expressed as a percentage increase of central SBP (AIxC1). 
For calculations we employed the PROC GLMPOWER 
procedure as implemented in SAS 9.2. Assuming the 
standard deviation of AIxC1 to be 10%, about 50 persons 
would be needed per allelic group to achieve 80% power 
at alpha of 0.05 to detect 5% between FDRNa group dif-
ference in AIxC1 in each allelic group, i.e. G vs A for 
G1675A polymorphism of AGTR2 gene, separately. In 
our study the groups comprised 46 and 52 individuals, for 
G and A alleles, respectively.
Results
Characteristics of the study population
The study population consisted of 131 patients, including 
66 men (50.3%) and 65 women (49.7%). The mean time 
from establishing the diagnosis of hypertension to enrol-
ment to the study was 11.7 years. The daily sodium intake 
assessed based on 24-hour urine collection was 
193.9±95.3 mmol. Male patients had higher BMI 
(30.4±4.3 vs 28.9±4.2 kg/m2, p=0.04), WHR (0.96±0.06 
vs 0.85±0.06, p<0.001) and Na24 (236.6±99.5 vs 
153.9±70.1 mmol/l, p<0.001) than female patients. 
However, no differences between the male and female 
patients were found for FENa (0.94±0.31 vs 0.81±0.19%, 
p=0.21) and the parameters calculated using the endoge-
nous lithium clearance: FELi (20.8 (15.0–34.7) vs 23.3 
(14.6–44.8)%, p=0.49) and FDRNa (96.0 (94.0–97.6) vs 
97.3 (95.3–98.1)%, p=0.07). Clinical parameters of the 
study group, as well as the parameters of blood pressure, 
arterial stiffness, biochemical measurements in blood and 
24-hour urine collections, calculated sodium, creatinine 
and lithium clearances and FENa, FELi and FDRNa in men 
and women analysed separately are summarised in Tables 
1 and 2. There were no gender differences with respect to 
the treatment with ACE-inhibitors, angiotensin-receptor 
blockers, calcium-channel blockers and beta-blockers in 
the groups analysed in the study (all p⩾0.12).
Factors determining the peripheral and central blood 
pressure values and arterial stiffness parameters includ-
ing PWV, AIxC1, AIxC2 and AIxP were established using 
simple linear regression. In the study group, PWV 
showed a positive relationship with age (β=0.09, stand-
ard error (SE)=0.03; p=0.01), WHR (β=0.06, SE=0.03; 
p=0.03), SBP (β=0.07, SE=0.01; p=0.001) and LV dys-
function (β=1.19, SE=0.56; p=0.03). AIxC1 showed 
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Table 1. Clinical characteristics and arterial stiffness parameters in the study population.
Male n=66 Female n=65 p
Clinical characteristics  
Age (years) 60.2 ± 7.4 64.2 ± 6.9 0.002
Height (cm) 174.9 ± 5.9 160.9 ± 6.5 0.001
Weight (kg) 93.0 ± 14.0 74.7 ± 11.5 0.001
BMI (kg/m2) 30.4 ± 4.3 28.9 ± 4.2 0.042
Waist (cm) 105.0 ± 10.8 93.3 ± 12.3 0.001
Hip (cm) 109.0 ± 8.3 109.7 ± 9.8 0.663
Waist-to-hip ratio (WHR) 0.96 ± 0.06 0.85 ± 0.06 0.001
Heart rate (beats/min) 69.8 ± 11.2 69.8 ± 8.7 0.995
SBP (mm Hg)a 144.4 ± 21.7 143.4 ± 20.0 0.775
DBP (mm Hg)a 83.1 ± 11.7 81.2 ± 10.3 0.344
MBP (mm Hg)a 103.5 ± 14.0 101.9 ± 12.3 0.498
PP (mm Hg)a 61.3 ± 15.2 62.1 ± 15.3 0.768
Arterial stiffness parameters  
PWV (m/s) 14.1 ± 3.0 13.2 ± 2.9 0.116
SBPC (mm Hg) 132.6 ± 21.3 132.8 ± 19.6 0.994
DBPC (mm Hg) 82.7 ± 11.4 80.3 ± 11.5 0.258
PPC (mm Hg) 50.3 ± 14.3 52.3 ± 14.1 0.424
AG (mm Hg) 15.1 ± 7.2 18.4 ± 8.1 0.019
AIxC1 (%) 142.6 ± 22.0 154.7 ± 21.7 0.003
AIxC2 (%) 28.8 ± 9.7 34.0 ± 9.4 0.003
AIxP (%) 87.1 ± 11.7 95.1 ± 13.1 0.001
AG: central pulse wave augmentation; AIxC1 and AIxC2: central pulse wave augmentation indexes; BMI: body mass index; DBP: diastolic blood  
pressure; DBPC: central diastolic blood pressure; MBP: mean blood pressure; PP: pulse pressure; PPC: central pulse pressure; PWV: pulse wave 
velocity; SBP: systolic blood pressure; SBPC: central systolic blood pressure.
The data are presented as arithmetical means, amean of three blood pressure measurements obtained at one visit.
Table 2. Biochemical studies in serum and 24-hour urine and the parameters obtained using endogenous lithium clearance in the 
study population. The data are presented as arithmetical mean ± SD and as median values with interquartile ranges.
Male n=66 Female n=65 p
Serum  
Creatinine (µmol/l) 80.8 ± 12.2 65.9 ± 13.1 0.001
Sodium (mmol/l) 140.6 ± 1.9 140.6 ± 2.2 0.962
Potassium (mmol/l) 4.3 ± 0.4 4.3 ± 0.3 0.836
Lithium (µmol/l) 0.14 (0.08–0.23) 0.15 (0.06–0.22) 0.692
24-hour urine  
Volume (l) 1.87 ± 0.66 1.67 ± 0.62 0.081
Creatinine excretion (mmol) 15.3 ± 3.7 9.4 ± 3.0 0.001
Sodium excretion (mmol) 236.6 ± 99.5 153.6 ± 70.5 0.001
Potassium excretion (mmol) 69.1 ± 24.1 51.1 ± 18.0 0.001
Albumin excretion (mg) 19.0 ± 24.4 20.1 ± 32.5 0.829
Albumin/creatinine ratio (mg/mmol) 1.2 ± 1.4 2.3 ± 4.7 0.080
Creatinine clearance (ml/min/1.73 m2) 135.3 ± 36.0 103.8 ± 36.2 0.963
Sodium clearance (ml/min/1.73 m2) 1.17 ± 0.50 0.77 ± 0.35 0.001
Endogenous lithium clearance  
Lithium excretion (µmol/24 h) 5.42 (3.80–7.47) 4.06 (2.72–6.01) 0.010
Lithium clearance (ml/min/1.73 m2) 26.0 (20.0–41.1) 23.6 (14.3–39.4) 0.066
FENa (%) 0.94 ± 0.61 0.81 ± 0.49 0.201
FELi (%) 20.8 (15.0–34.7) 23.3 (14.6–44.8) 0.495
FDRNa (%) 96.0 (94.0–97.6) 97.3 (95.3–98.1) 0.065
FENa; fractional urinary sodium excretion; FELi; fractional urinary lithium excretion; FDRNa: fractional sodium reabsorption in distal tubules.
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positive relation with age (β=0.70, SE=0.27; p=0.01), 
female sex (β=12.25, SE=3.87; p=0.002) and SBP 
(β=0.18, SE=0.09; p=0.05), and negative relation with 
WHR (β=−0.58, SE=0.23; p=0.01). AIxC2 showed posi-
tive relation with age (β=0.35, SE=0.12; p=0.004), 
female sex (β=5.37, SE=1.69; p=0.002) and SBP (β=0.09, 
SE=0.04; p=0.04), and negative relation with WHR 
(β=−0.29, SE=0.10; p=0.04). AIxP showed positive rela-
tion with age (β=0.42, SE=0.16; p=0.008), female sex 
(β=8.23, SE=2.23; p=0.0003) and SBP (β=0.12, SE=0.05; 
p=0.02), and negative relation with WHR (β=−0.42, 
SE=0.13; p=0.002). On the basis of the obtained data, 
arterial stiffness parameters were standardised for age, 
sex, SBP, WHR, antihypertensive treatment and presence 
or absence of diastolic LV dysfunction.
The distributions of the analysed polymorphisms of 
the AGTR1 and AGTR2 genes were consistent with the 
Hardy-Weinberg principle: AGTR1 A1166C gene poly-
morphism (p=0.42) and AGTR2 G1675A gene polymor-
phism (p=0.79). The respective frequencies of the 
genotypes of the AGTR1 A1166C polymorphism were as 
follows: AA genotype (52.6%), AC genotype (39.1%) 
and CC genotype (8.3%), while the respective frequen-
cies of the A and C allele were 72.6% and 27.4%, respec-
tively. As the AGTR2 G1675A polymorphism is located 
on the X chromosome, further analyses were performed 
in men and women separately. In women, the respective 
frequencies of the genotypes were as follows: GG geno-
type (24.6%), GA genotype (50.8%) and AA genotype 
(24.6%). The frequencies of the G and A allele in women 
were 50.0% and 50.0% and in men were 45.6% and 
54.6%, respectively.
Relationships of the AGTR1 A1166C 
polymorphism and sodium parameters with 
respect to peripheral and central blood 
pressures and arterial stiffness parameters
For AGTR1 A1166C polymorphism, in the entire popula-
tion and in male and female patients analysed separately, 
we found no statistically significant differences between 
the patients with various genotypes and the peripheral (all 
p⩾0.15), central (all p⩾0.27) blood pressures and arterial 
stiffness parameters: PWV (p⩾0.85), AIxC1 (P⩾0.58), 
AIxC2 (p⩾0.63) and AIxP (p⩾0.62).
To demonstrate the relationships between sodium 
parameters and the genotypes of the AGTR1 A1166C poly-
morphism and their combined influence on blood pressure 
and arterial stiffness parameters we analysed the interac-
tions between such polymorphism and FELi (all pINT⩾0.10), 
FDRNa (all pNT⩾0.14) and Na24 (all pNT⩾0.22). Moreover, 
in the analyses of the relationships with AGTR1 A1166C 
genotypes and sex, no statistically significant interactions 
were observed with respect to blood pressure and arterial 
stiffness parameters (all pINT⩾0.71).
Relationships of the AGTR2 G1675A 
polymorphism and sodium parameters with 
respect to peripheral and central blood 
pressures and arterial stiffness parameters
The analyses of the relationships of the AGTR2 G1675A 
polymorphism, conducted both in the whole study group 
and in the subgroups of male and female patients, revealed 
no significant differences between the allele carriers and 
patients with various genotypes of the polymorphism with 
respect to blood pressures (Table 3), as well as arterial 
stiffness parameters (Table 4).
To demonstrate the relationships between sodium 
parameters and the genotypes of the AGTR2 G1675A pol-
ymorphism and their combined influence on blood pres-
sure and arterial stiffness parameters, in male and female 
patients separately, we analysed the interactions between 
such polymorphism and FELi, FDRNa and Na24. The analy-
ses of the polymorphism interactions with FELi (male: 
0.08⩽ pINT⩽0.93; female: 0.17⩽ pINT⩽0.91) and Na24 
(male: 0.06⩽ pINT ⩽0.33; female: 0.09⩽pINT⩽0.73) 
revealed no statistically significant interactions with 
respect to blood pressure and arterial stiffness parameters.
However, in men we revealed statistically significant 
relationships between the AGTR2 G1675A polymorphism 
and FDRNa with respect to AIxC1: pINT=0.01, AIxC2: 
pINT=0.05 and AIxP: pINT=0.006. In the analyses of the 
relationships with FDRNa in the women group, no statisti-
cally significant interactions were observed with respect to 
peripheral (0.21⩽p⩽0.34), central (0.08⩽pINT ⩽0.33) 
blood pressures and arterial stiffness parameters 
(0.09⩽pINT ⩽0.98). In both sexes combined (with exclu-
sion of heterozygous women), we observed statistically 
significant relationships between the AGTR2 G1675A 
polymorphism and FDRNa with respect to AIxC1: pINT=0.01, 
AIxC2: pINT=0.04 and AIxP: pINT=0.01.
Thus, the subsequent analyses of the relationships 
between arterial stiffness parameters and the AGTR2 
G1675A polymorphism were conducted using multifacto-
rial regression analysis for the subgroups with sex-specific 
distribution of FDRNa below and above the median value. 
In 30 G allele carrying men, AIxC1 (17.3% increase per 5% 
higher FDRNa; p=0.05) and AIxP (11.1% increase per 5% 
higher FDRNa; p=0.01) with the similar trend for AIxC2, 
arterial stiffness increased with higher sodium reabsorp-
tion in distal tubule, with the opposite tendency in A allele 
carriers. On the other hand, in 36 A allele carrier men, 
AIxC1 (8.7% borderline insignificantly decreasing per 5% 
higher FDRNa; p=0.06) with the similar trend for AIxC2 and 
AIxP, arterial stiffness decreased with higher sodium reab-
sorption in distal tubule. Additionally, in the subgroup 
with FDRNa below the sex-specific median (96%) value, 
AIxC1 was 15.8% higher (p=0.004), AIxC2 was 7.1% higher 
(p=0.01) and AIxP was 10.0% higher (p=0.007) in the A 
allele compared with the G allele carriers.
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Comparative analysis of the relationships between 
arterial stiffness parameters and the AGTR2 G1675A 
polymorphism were also conducted in women in the sub-
groups with FDRNa, below and above the sex-specific 
Table 3. Analysis of the relationships between peripheral and central blood pressures and the AGTR2 G1675A polymorphism in 
the male and female patients.
Phenotype Standardised mean ± SE p
Male G .…. A  
Number 60 .…. 72  
SBP, mm Hg 144.6 ± 3.9 .…. 144.3 ± 3.5 0.954
DBP, mm Hg 82.3 ± 2.1 .…. 83.7 ± 2.1 0.603
MBP, mm Hg 103.0 ± 2.5 …… 103.9 ± 2.5 0.798
PP, mm Hg 62.3 ± 2.8 …… 60.5 ± 2.5 0.639
SBPC, mm Hg 132.1 ± 4.0 …… 132.9 ± 3.5 0.889
DBPC, mm Hg 83.0 ± 2.1 .…. 82.4 ± 1.8 0.847
PPC, mm Hg 49.0 ± 2.7 .…. 51.2 ± 2.3 0.532
AG, mm Hg 14.2 ± 1.4 .…. 15.8 ± 1.2 0.400
Female GG GA AA  
Number 16 33 16  
SBP, mm Hg 143.3 ± 4.7 142.7 ± 3.3 144.9 ± 4.9 0.943
DBP, mm Hg 80.0 ± 2.4 82.3 ± 1.7 80.2 ± 2.6 0.668
MBP, mm Hg 101.1 ± 2.9 102.5 ± 2.1 101.7 ± 3.0 0.926
PP, mm Hg 63.3 ± 3.6 60.4 ± 2.6 64.7 ± 3.8 0.613
SBPC, mm Hg 129.9 ± 4.8 133.9 ± 3.3 133.5 ± 4.7 0.786
DBPC, mm Hg 78.5 ± 3.0 81.5 ± 2.1 79.8 ± 2.9 0.708
PPC, mm Hg 50.2 ± 3.4 53.3 ± 2.3 52.5 ± 3.3 0.765
AG, mm Hg 17.1 ± 1.9 19.2 ± 1.3 17.9 ± 1.8 0.649
AG: central pulse wave augmentation; DBP: diastolic blood pressure; DBPC: central diastolic blood pressure; MBP: mean blood pressure; PP: pulse 
pressure; PPC: central pulse pressure; SBP: systolic blood pressure; SBPC: central systolic blood pressure.
The data were standardised for age, waist-to-hip ratio (WHR), antihypertensive treatment and presence or absence of left ventricular (LV) diastolic 
dysfunction. Blood pressure parameters are presented as standardised arithmetic mean ± standard error (SE). Values of p refer to the differences 
between the G and A alleles and between the GG, GA and AA genotypes.
Table 4. Analysis of the relationships between arterial stiffness parameters and the AGTR2 G1675A polymorphism in the male and 
female patients.
Phenotype Standardised mean±SE p
Male G .…. A  
Number 60 .…. 72  
PWV, m/s 13.8 ± 0.5 .…. 14.3 ± 0.5 0.547
AIxC1, % 141.2 ± 4.3 .…. 143.7 ± 3.7 0.677
AIxC2, % 26.9 ± 1.9 .…. 30.3 ± 1.6 0.193
AIxP, % 84.9 ± 2.3 .…. 88.7 ± 2.0 0.234
Female GG GA AA  
Number 16 33 16  
PWV, m/sek 13.4 ± 0.7 13.3 ± 0.5 13.0 ± 0.7 0.903
AIxC1, % 153.8 ± 5.4 156.3 ± 3.8 152.4 ± 5.3 0.829
AIxC2, % 32.4 ± 2.3 35.7 ± 1.6 32.3 ± 2.2 0.353
AIxP, % 93.6 ± 3.1 96.8 ± 2.1 93.2 ± 3.2 0.561
AIxC1 and AIxC2: central pulse wave augmentation indexes; AIxP: peripheral pulse wave augmentation index; PWV: pulse wave velocity.
The data were standardised for age, waist-to-hip ratio (WHR), systolic blood pressure (SBP), antihypertensive treatment and presence or absence of 
left ventricular (LV) diastolic dysfunction. Arterial stiffness parameters are presented as standardised arithmetic mean±standard error (SE). Values of 
p refer to the differences between the G and A alleles and between the GG, GA and AA genotypes.
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median (97.4%) value and no significant differences 
were observed. However, in both sexes combined (with 
the exclusion of heterozygous women), we received con-
vergent results. In 46 G allele carriers, AIxC1 (15.3% 
increasing per 5% higher FDRNa; p=0.05) and AIxP (9.2% 
increasing per 5% higher FDRNa; p=0.02) with the simi-
lar trend for AIxC2, arterial stiffness increased with higher 
sodium reabsorption in the distal tubule, with the oppo-
site tendency in A allele carriers. On the other hand, in 52 
A allele carriers, AIxC1 did not significantly decrease 
(6.5% decrease per 5% higher FDRNa; p=0.07) with the 
similar trend for AIxC2 and AIxP, arterial stiffness 
decreased with higher sodium reabsorption in the distal 
tubule. Additionally, in the subgroup with FDRNa below 
the all-population median (96.5%) value, AIxC1 was 
10.9% higher (p=0.02), AIxC2 was 5.5% higher (p=0.02) 
and AIxP was 7.3% higher (p=0.02) in the A allele com-
pared with the G allele carriers. The analysis of the rela-
tionships of the AGTR2 G1675A polymorphism with 
arterial stiffness parameters in the subgroups with FDRNa 
below and above the sex-specific for men and all-group 
median value are presented on Figure 1.
Discussion
Our study, conducted in a population characterised by 
high dietary sodium intake and long-standing history of 
hypertension, revealed that increased sodium reabsorp-
tion in distal tubules is related to the development of arte-
rial stiffness, which, in turn, is related to the expression 
of the AGTR2 G1675A polymorphism. Further, we found 
this relation to be independent of blood pressure values. 
In men and in both sexes combined (with the exclusion of 
heterozygous women), AIxC1 and AIxP increased with 
higher sodium reabsorption in distal tubule, in the pres-
ence of AGTR2 G allele with the opposite tendency in A 
allele carriers. In G allele carrying men and GG homozy-
gous women, the AIxC1 (139.6±3.8 vs 159.1±5.7%; 
p=0.009), AIxC2 (26.3±1.8 vs 33.3±1.7%; p=0.016) and 
AIxP (83.4±2.5 vs 96.5±2.6%; p<0.0001) were lower in 
the subgroup with FDRNa below the median value, com-
pared to the subgroup with FDRNa above the median 
value. Our results indicating the relationship of the 
increased distal sodium reabsorption, as measured using 
endogenous lithium clearance, with the AGTR2 G1675A 
polymorphism with respect to arterial stiffness parame-
ters, are to the best of our knowledge the first such data in 
the literature. The AGTR1 A1166C polymorphism was 
unrelated to arterial stiffness.
The progressive interstitial and perivascular fibrosis, 
induced in part by AT II, contribute to an increase in arte-
rial and cardiac muscle remodelling/hypertrophy and 
development of hypertension and diastolic dysfunction. 
Of the two major AT II receptor isoforms, AT1 and AT2, 
it is generally accepted that most of the traditional AT II 
functions in the cardiovascular system are attributable to 
AT1. The anti-proliferative actions of the AT2 receptor 
offset the growth promoting effects mediated by the 
AT1.7 However, several reports of in vivo as well as in 
vitro studies elucidated roles of AT2 in medial hypertro-
phy and fibrosis in aorta,20 heart21 and cultured cells.22 
Levy et al.20 demonstrated that chronic AT2 blockade in 
AT II–induced hypertensive rats markedly suppressed 
arterial hypertrophy and fibrosis and proposed that the 
vasotrophic effects of AT II may be at least partially 
mediated via the AT2 receptor. This effect may be due to 
the fact that the AT2 receptor is expressed at low levels in 
normal tissues but upregulated in pathological states, 
including hypertension, vascular injury, myocardial 
infarction, stroke and heart failure.23
The AGT2R G1675A polymorphism is located on the 
X chromosome and consists of three exons interspaced by 
two introns. Regulatory elements are located in the pro-
moter area and in the first intron, whereas the third exon 
contains the complete protein-coding sequence, which 
encode the 363-amino acid G-protein-coupled receptor.24 
AGTR2 gene contains several polymorphic sites. A com-
mon G/A polymorphism occurs at position (rs1403543) 
relative to the transcription start. It is also known as 
G1332A relative to the start codon in the first intron. The 
G1675A polymorphism is probably functional and leads 
to differences in AT2 receptor expression,25 however, 
studies on cell cultures yield conflicting results regarding 
the roles of particular alleles.26 The studies did confirm 
that AGTR2 G1675A polymorphism may lead to differ-
ences in AT2 receptor expression. Warnecke et al.25 indi-
cated that individuals carrying the G allele may express 
higher levels of AT2 receptor protein, however another 
study suggested that the A allele might be associated with 
increased AT2 receptor transcription.26
The current literature which abounds in studies on 
the relation between the G1675A (equivalent to G1332A) 
AGTR2 gene polymorphism and the cardiovascular risk fac-
tors, predominantly the various indices of LV hypertrophy, 
shows conflicting results. Schmieder et al.27 found in 120 
young men with normal or mildly elevated blood pressure, 
that hypertensive but not normotensive A allele carriers had 
a higher LV mass (LVM) and LV mass index (LVMI) than 
G allele carriers, because of an increased wall thickness. 
Likewise, in a study by Herrmann et al.,28 AGTR2 A allele 
carriers were more common in males with ECG LV hyper-
trophy, than in those without hypertrophy. However, in older 
hypertensive patients, LVM as measured by magnetic reso-
nance imaging was higher in AGTR2 G allele carriers.29
In a study based on the European Project On Genes 
in Hypertension (EPOGH) database published by 
Kuznetsowa et al.,18 the effect of the AGTR2 G1675A 
polymorphism on LVM differed according to sodium 
intake. Without taking sodium excretion into account, 
there was no difference in LVMI between carriers of the G 
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Figure 1. Parameters of arterial stiffness in the G and A allele carriers of the AGTR2 G1675A gene polymorphism in the 
subgroups with fractional sodium reabsorption in distal tubules (FDRNa) below and above the sex-specific for men and all-group 
median value. The data in the median FDRNa subgroups were standardised for age, sex, SBPWHR, antihypertensive treatment and 
presence or absence of diastolic LV dysfunction. The data were presented as arithmetic means±standard error (SE). Values of p 
indicate the difference of stiffness parameters in the G-allele carriers, according to FDRNa level (above or below median). AIxC1 and 
AIxC2: central pulse wave augmentation indexes; AIxP: peripheral pulse wave augmentation index.
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or A allele. However, in man and in both sexes combined 
with exclusion of heterozygous women, LVMI and LV 
internal diameter increased with higher sodium excretion 
in the presence of G allele with the opposite tendency in A 
allele carriers. Further analyses dichotomised according 
to median sodium excretion showed that when sodium 
excretion was below the median, LVMI was lower in G 
than A allele carriers. This association has been validated 
in a study involving of young Caucasian males with and 
without mild hypertension with results in line with those 
of an earlier study.27 After accounting for sodium, LVM 
was higher in the G allele carriers with high rather than 
low salt intake, in blood pressure independent fashion.30 
Both studies conform that AGTR2 G allele appears to be 
susceptible to a modifying effect of increased salt intake 
on LVM. Some other studies also reported the association 
of the G allele with hypertension and salt sensitivity.31 
The aforementioned results are stand in line with our own 
data on vascular stiffness parameters, where likewise 
independent of blood pressure, the renal sodium handling 
(assessed by FDRNa) turned out to modify gene effects. 
The studies in animal models strengthen the evidence by 
indicating that dietary sodium depletion increases the 
expression and density of the AT2 receptor in mature adult 
rat kidneys.32 Renal AT2 receptors, through their influ-
ence on sodium balance and the circulating plasma vol-
ume, might at least partly explain these findings.
Studies on spontaneously hypertensive rats (SHRs) 
revealed that increased dietary sodium intake is associated 
with vascular33 and myocardial34 hypertrophy and remod-
elling which involved not only an increased tunica media 
thickness but also an elevated extracellular elastin and col-
lagen. Of the diagnostic methods available for many years 
in studies on sodium sensitivity in hypertension the assess-
ment of sodium reabsorption in the proximal and distal 
renal tubules using endogenous lithium clearance again 
comes to light. Only a limited number of publications on 
cardiovascular remodelling and target organ damage of 
hypertension included endogenous lithium clearance 
measurements. Seidlerova et al.10 studied 1069 untreated 
subjects from the general population. They observed the 
relationships between the increased diameter of the bra-
chial artery and increased sodium reabsorption in proximal 
tubule (FPRNa) and between the impaired compliance and 
distensibility of femoral artery and increased FDRNa. Jin 
et al.11 analysed the parameters of LV hypertrophy in the 
context of sodium parameters. They showed an independ-
ent increase of LVMI associated with an increased 24-hour 
urinary sodium excretion. The authors also analysed the 
effects of increased FPRNa and FDRNa in the context of 
LVMI increase and found no relationship; however, the 
increase of FDRNa affected indirect parameters of LV 
hypertrophy. In our study we found statistically significant 
relationships between the AGTR2 G1675A polymorphism 
and FDRNa with respect to arterial stiffness parameters of 
AIxC1, AIxC2 and AIxP. However, we did not find such a 
relationship for FELi and Na24, and the analysed indices of 
sodium load are each other closely related to each other. 
Before and after the standardisation FDRNa showed sig-
nificant negative correlation with Na24 (partial r=−0.36; 
p<0.0001), suggesting association between increased 
sodium intake and decreased sodium reabsorption in the 
distal tubule, and significant positive correlation with FELi 
(partial r=0.52; p<0.0001). These results are concordant 
with the ones derived from a general population.10 In this 
context, FRDNa seems to emerge stronger than the Na24 
modulator of sodium-dependent genetic polymorphism-
cardiovascular phenotype response to sodium overload.
Our study should be interpreted in the context of its 
limitations and strengths. The main limitation was that the 
study group of only 131 subjects did not allow for meas-
urements in the respective tertiles of FDRNa because of 
limited numbers of patients in the groups. The second limi-
tation related to the enrolment of patients with long-stand-
ing hypertension to the studies on renal sodium regulation 
lies in the fact that they are treated with antihypertensive 
drugs. To avoid the interference of diuretics with renal 
sodium excretion and reabsorption the patients enrolled in 
the study were required to receive no long-term diuretic 
therapy or to have their hypertension controlled effectively 
enough to allow the discontinuation of diuretics at least 
five days before the enrolment. Nevertheless, other drugs, 
including ACE-inhibitors, angiotensin-receptor blockers, 
calcium channel blockers and beta-blockers were not dis-
continued for both ethical and medical reasons. This is cer-
tainly the most important limitation of our study. This 
issue is particularly important in the case of ACE-inhibitors 
and angiotensin-receptor blockers, as they increase renal 
blood flow and decrease both total and fractional sodium 
reabsorption. Nevertheless, in the case of ACE-inhibitors 
it has been observed that this effect was more pronounced 
in persons with high activity of the RAA system, which is 
observed in normal subjects with low dietary sodium 
intake.12 Finally the enrolment was a non-randomised pro-
cedure. However, the key inclusion criterion was homog-
enous age, which allowed for the selection of two 
sex-specific groups with virtually no age difference. On 
the other hand, our results need separate confirmation in 
larger groups of patients, in a study powered enough to 
analyse men and women separately.
Conclusions
Target organ damage, as an intermediate phenotype, has 
been linked in many studies with cardiovascular compli-
cations. Thus our inferences based on the assessment of 
such entities as vascular structure and function can to 
some extent shed mechanistic light upon the disparate 
results of recent epidemiologic studies which assessed 
relation between sodium consumption and cardiovascular 
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outcome. In the study by Stolarz-Skrzypek et al.1 esti-
mated sodium consumption was not related to hard car-
diovascular outcome. However, the authors based their 
estimates on a pool of data obtained from healthy popula-
tions based on the nuclear-family principle. Another large 
study showed that there was a J-shaped relationship 
between sodium intake and risk of cardiovascular compli-
cations.2 Neither study included genetic factors. It is pos-
sible, that the mutated polymorphism of the AT II gene 
stays phenotypically dormant in normotensive individu-
als, but its potentiating action reveals itself in the context 
of both hypertension and high sodium load, in individuals 
with impeded renal sodium handling. Such a hypothesis 
needs further testing, but can be a part of a unifying mech-
anistic explanation for the puzzling epidemiologic results.
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